Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Progressive Corp — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.96 (market cap $1.74B), while Progressive Corp trades at $218.35 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 73× Nuvation Bio Inc. Class A Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Progressive Corp for 81 Days on average.
| NUVB | PGR | |
|---|---|---|
Market Cap | $1.74B | $126.95B |
Volume | 9,289,619 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $9.54 | $242.16 |
52-Week Low | $3.41 | $190.40 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $1.33B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and robust profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed. Analyst consensus leans neutral with 52.38% hold ratings but a $222.23 price target suggests modest upside potential from current levels.
PGR presents a balanced investment case with solid fundamentals and reasonable valuation (P/E 10.97) offset by competitive pressures in personal auto insurance. The stock's technical strength and consistent revenue growth support potential upside, though investors should monitor underwriting discipline amid intensifying market competition. Key risks include execution challenges and macroeconomic sensitivity affecting insurance demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
